|Bid||4.4600 x 1000|
|Ask||4.4700 x 1000|
|Day's Range||4.3900 - 4.5000|
|52 Week Range||1.7400 - 10.5700|
|Beta (5Y Monthly)||2.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 18, 2012|
|1y Target Est||10.80|
Bristol Myers Squibb said on Monday the U.S. health regulator has deferred a decision on an experimental blood cancer therapy that it acquired in the $74 billion buyout of Celgene due to coronavirus-related travel restrictions. The U.S. Food and Drug Administration (FDA) was unable to inspect a third-party manufacturing facility in Texas, a step required before the approval of the drug liso-cel, the company said. Bristol Myers said on Monday the agency had deferred its application until the inspection can be completed.
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
SPPI earnings call for the period ending September 30, 2020.